The new COX-2 inhibitor valdecoxib (Bextra®) appears to be less likely to bother osteoarthritis (OA) patients with signs and symptoms of dyspepsia than either ibuprofen or diclofenac.
The findings were presented here this week at the Annual European Congress of Rheumatology (EULAR). As part of a multicenter trial, Dr. B.M Peña, MPH, from Pfizer Pharmaceuticals Group, New York, United States, and colleagues randomized OA patients to treatment with valdecoxib 10 mg or 20 mg daily, ibuprofen 800 mg TID, diclofenac 75 mg BID, or placebo.
Researchers administered the Severity of Dyspepsia Assessment (SODA) Questionnaire to 1,052 patients before starting treatment and repeatedly throughout the study until its end at 12 weeks. Of these patients, 204 were on the lower dose of valdecoxib, 219 were on the higher dose, 207 were on ibuprofen, 212 were on diclofenac, and 210 were on placebo. This questionnaire includes three scales, which measured pain intensity, non-pain symptoms, and satisfaction.
e-Med Tools
קצר קולע וממוקד
e-Med סמינרים
אי-מד תחקירים
Medscape Tools
Journal Club
מרכזי מידע ושירות
Facebook
מידע למפרסם
מאגר תרופות
מאגר אנשי המקצוע
אינדקס שימושי
חדשות משה"ב
eMed HealthClub
מחקרים קליניים
השאירו תגובה
רוצה להצטרף לדיון?תרגישו חופשי לתרום!